News

The granted claims of the patent include an invention directed towards producing constructs for RNA interference (RNAi) techniques. The invention provides a ribonucleic acid (RNA) for use as

The Phase II study will enroll 80 patients with advanced head and neck, and non-small cell lung cancer at the National Center for Rehabilitative Auditory Research at the

This new trial is intended to evaluate the safety and immunogenicity of an improved formulation of the vaccine containing an adjuvant that is expected to result in long

Under terms of the agreement, Sonus was granted exclusive rights to develop two core compounds for all prophylactic and therapeutic uses in humans. Additionally, Sonus was granted rights

In a 173-patient, placebo and active comparator-controlled double blind Phase III study with a seven-week open label follow on, IPX056 was shown to be effective versus placebo in

The company is producing up to 40 million doses of Fluvirin, with the World Health Organization recommended change in all three virus strains included in the influenza vaccine

The Reply pacemaker which is said to be the world’s smallest dual chamber pacemaker at 8cc’s is Sorin Group’s next pacing evolution designed to reduce ventricular pacing and

Thomas Kindt, chief scientific officer of InNexus, said: “We are beginning a study in cynomolgus monkeys of DXL625, an antibody directed against the B-cell marker CD20 and enhanced

The technology, which will be used by Covidien’s respiratory and monitoring solutions business unit, reflects the company’s strong commitment to making investments in clinically relevant product innovations designed